Meira G Tx Holdings PLC MGTX
We take great care to ensure that the data presented and summarized in this overview for MeiraGTx Holdings plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MGTX
View all-
Perceptive Advisors LLC New York, NY12.6MShares$92.2 Million3.61% of portfolio
-
Johnson & Johnson New Brunswick, NJ6.64MShares$48.5 Million14.56% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.03MShares$44.1 Million0.07% of portfolio
-
Prosight Management, LP Dallas, TX4.59MShares$33.5 Million8.1% of portfolio
-
Rubric Capital Management LP New York, NY3.73MShares$27.2 Million0.56% of portfolio
-
683 Capital Management, LLC New York, NY2.69MShares$19.6 Million1.37% of portfolio
-
Black Rock Inc. New York, NY2.52MShares$18.4 Million0.0% of portfolio
-
J. Goldman & CO LP New York, NY2.04MShares$14.9 Million0.36% of portfolio
-
Knoll Capital Management, LLC Miami, FL1.25MShares$9.13 Million5.54% of portfolio
-
Erste Asset Management Gmb H Vienna, C4790KShares$5.76 Million0.04% of portfolio
Latest Institutional Activity in MGTX
Top Purchases
Top Sells
About MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Insider Transactions at MGTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2025
|
Richard Giroux CFO & COO |
SELL
Open market or private sale
|
Direct |
24,000
-2.74%
|
$192,000
$8.52 P/Share
|
|
Jul 08
2025
|
Alexandria Forbes PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
47,500
-3.37%
|
$332,500
$7.97 P/Share
|
|
Jun 30
2025
|
Richard Giroux CFO & COO |
SELL
Bona fide gift
|
Direct |
5,000
-0.57%
|
-
|
|
Jun 06
2025
|
Keith R. Harris |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+37.5%
|
-
|
|
Apr 22
2025
|
Richard Giroux CFO & COO |
SELL
Open market or private sale
|
Direct |
24,000
-2.65%
|
$144,000
$6.0 P/Share
|
|
Apr 08
2025
|
Alexandria Forbes PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
47,500
-3.26%
|
$237,500
$5.34 P/Share
|
|
Feb 21
2025
|
Robert J Wollin GENERAL COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
12,116
-28.01%
|
$84,812
$7.3 P/Share
|
|
Feb 21
2025
|
Robert J Wollin GENERAL COUNSEL AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+34.21%
|
-
|
|
Feb 21
2025
|
Robert K Zeldin CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,903
-4.14%
|
$41,321
$7.3 P/Share
|
|
Feb 21
2025
|
Robert K Zeldin CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+9.53%
|
-
|
|
Feb 21
2025
|
Alexandria Forbes PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
66,095
-4.34%
|
$462,665
$7.3 P/Share
|
|
Feb 21
2025
|
Alexandria Forbes PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+7.59%
|
-
|
|
Feb 21
2025
|
Richard Giroux CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
63,452
-6.54%
|
$444,164
$7.3 P/Share
|
|
Feb 21
2025
|
Richard Giroux CFO & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
120,000
+11.01%
|
-
|
|
Feb 21
2025
|
Stuart Naylor CHIEF DEV. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,500
-3.63%
|
$164,500
$7.3 P/Share
|
|
Feb 21
2025
|
Stuart Naylor CHIEF DEV. OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.18%
|
-
|
|
Jan 21
2025
|
Richard Giroux CFO & COO |
SELL
Open market or private sale
|
Direct |
24,000
-2.75%
|
$144,000
$6.29 P/Share
|
|
Jan 14
2025
|
Stuart Naylor CHIEF DEV. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,163
-1.84%
|
$55,815
$5.77 P/Share
|
|
Jan 14
2025
|
Stuart Naylor CHIEF DEV. OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,750
+3.76%
|
-
|
|
Jan 14
2025
|
Robert J Wollin GENERAL COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
2,909
-12.29%
|
$14,545
$5.77 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 706K shares |
|---|
| Payment of exercise price or tax liability | 319K shares |
|---|---|
| Open market or private sale | 215K shares |
| Bona fide gift | 5K shares |